Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L1-79 in adolescent and young adult males with autism
NCT02947048Phase 2Completed
- Sponsor
- Yamo Pharmaceuticals
- Start
- Oct 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of L1-79 in Autism Spectrum Disorder (ASD), sponsored by Yamo Pharmaceuticals. Started Oct 2016; status: completed.
02
Drugs
L1-79
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02947048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947048.